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that tailored treatment in rheumatoid arthritis patients
is an important topic to address [1]. Current guidelines
promote the use of prognostic factors in treatment
decisions [2], but perspectives on the predicted outcome
vary. Although current treatment strategies suppress
radiographic progression in most patients, rapid clinical
improvement (RCI) remains relevant for functional res-
toration [3]. We aimed to predict RCI in patients with a
poor prognosis (PP) and with a nonpoor prognosis
(non-PP). We based classification on prognostic factors
mentioned in the European League Against Rheumatism
recommendations (method 1) [2] and, for confirmation,
on the Visser model (method 2), despite its focus on pre-
dicting rapid radiographic progression (RRP) [4]. We did
not aim to compare both methods for superiority, but as
our colleagues propose this approach we need to reiter-
ate some of the numbers to accomplish accurate inter-
pretation of our results.
First, of the PP patients following Visser’s model
(defined as having >50 % RRP risk) receiving initial
monotherapy (iMono), 46 % (not 64 %, as our colleagues
mention) in fact developed RRP (Table S1 in [5]). As
concluded previously, this model predicts RRP better
than method 1, in which 26 % of PP patients developed
RRP. However, we were interested in predicting RCI.* Correspondence: i.m.markusse@lumc.nl
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creativecommons.org/publicdomain/zero/1.0/Second, the separation in the Health Assessment Ques-
tionnaire for PP patients versus non-PP patients treated
with initial combination therapy (iCombo) (Figure S1 in
[5]) is 0.11 to 0.13 per time point; that is, not clinically
relevant differences [6]. However, relevant differences in
the Health Assessment Questionnaire were shown after
3 months, when comparing iMono with iCombo both in
PP and in non-PP patients using methods 1 and 2 (Table
S1 in [5]).
Last, our colleagues attempt to compare both methods
for predicting American College of Rheumatology 20/
50/70 response on iCombo or on iMono in PP patients
and non-PP patients. However, all odds ratios listed were
determined with Visser’s method. Odds ratios determined
using method 1 (Table 1) were not published previously.
Comparing methods 1 and 2, the 95 % confidence inter-
vals are largely overlapping, making it impossible to con-
clude that one method is superior in predicting American
College of Rheumatology response without advanced
statistics. These results indicate that, regardless of the
method, both PP patients and non-PP patients benefit
from iCombo, achieving RCI (Table 1).
We maintain that with currently known predictors it
is still impossible to define a subgroup that will achieve
equal RCI on iMono as that on iCombo. Future research
may reveal prognostic factors enabling us to stratify pa-article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Odds ratios for achieving ACR response after 3 months for patients treated with initial combination therapy compared with
initial monotherapy
Method 1 Method 2 (Visser model)
Odds ratio 95 % confidence interval Odds ratio 95 % confidence interval
Poor prognosis patients
ACR20 3.94 2.09 to 7.43 10.00 3.41 to 29.32
ACR50 6.29 3.00 to 13.20 9.74 3.22 to 29.49
ACR70 7.08 2.31 to 21.70 9.33 1.97 to 44.21
Nonpoor prognosis patients
ACR20 3.12 1.73 to 5.63 2.72 1.67 to 4.45
ACR50 6.25 3.08 to 12.70 5.39 2.98 to 9.74
ACR70 6.39 1.84 to 22.23 4.99 1.85 to 13.46
ACR, American College of Rheumatology
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patients achieve RCI on iCombo than on iMono. This
may constitute overtreatment if aiming to prevent future
radiographic damage, but prevents undertreatment of
debilitating arthritis already present.
Abbreviations
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